Ruplizumab

Ruplizumab (trade name Antova) is a humanized monoclonal antibody intended for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis. A study showed that the drug was associated with life-threatening thromboembolisms,[1] while another study only found thrombocytopenia.[2]

Ruplizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetCD154
Clinical data
Trade namesAntova
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
 NY (what is this?)  (verify)

References
  1. Liossis SN, Sfikakis PP (2004). "Costimulation blockade in the treatment of rheumatic diseases". BioDrugs. 18 (2): 95–102. doi:10.2165/00063030-200418020-00003. PMID 15046525. S2CID 24762590.
  2. Nakamura M, Tanaka Y, Satoh T, Kawai M, Hirakata M, Kaburaki J, et al. (February 2006). "Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism". Rheumatology. 45 (2): 150–6. doi:10.1093/rheumatology/kei118. PMID 16188945.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.